Why Farbe Firma is the Top Manufacturer of Parecoxib for Injection
- Maulik Sudani
- Jun 27
- 9 min read
Last Updated: June 27, 2026
TL;DR: Parecoxib for Injection - a sterile, lyophilized powder of parecoxib sodium, the water-soluble prodrug of valdecoxib and the only injectable selective COX-2 inhibitor (coxib) in clinical use, supplied commonly as a 40 mg vial reconstituted with 2 mL of 0.9% sodium chloride and given intravenously or intramuscularly - is the non-opioid analgesic clinicians use for the short-term management of acute post-operative pain, where COX-2 selectivity spares platelet function and the gastric mucosa relative to traditional NSAIDs. Because the active is a prodrug that is converted in the body to valdecoxib and is freeze-dried to a powder reconstituted at the bedside with a compatible diluent, each vial must deliver an exact, sterile, particulate-free dose at the labelled strength, with the stability-indicating assay, the related-substance (including valdecoxib) profile, the controlled residual moisture, reconstitution-and-diluent compatibility, fill and content uniformity, low particulate and endotoxin, a validated lyophilization and sterilisation process and verified container-closure integrity all mattering to safety and shelf life. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Parecoxib for Injection at our Gujarat, India facility and supplies it to surgical, anaesthesia, pain-management and hospital-pharmacy services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Selective COX-2 inhibitor (coxib) NSAID and prodrug - parecoxib sodium is rapidly converted in the body to valdecoxib, which selectively inhibits COX-2 to control pain and inflammation while largely sparing platelets and the gastric mucosa, and Parecoxib for Injection (40 mg lyophilized powder reconstituted with 0.9% sodium chloride, intravenous or intramuscular) demands an exact, reproducible parenteral dose for short-term post-operative pain.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, validated freeze-drying (lyophilization) and aseptic vial filling lines, control of the stability-indicating assay, the related-substance (including valdecoxib) profile, residual moisture, reconstitution and diluent compatibility, fill and content uniformity, particulate and endotoxin, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, lyophilization-cycle and reconstituted in-use and diluent-compatibility stability data, stability-indicating method-validation data, sterilisation and container-closure data, drug master files and CEP-style documentation for registrations including ministry-of-health, hospital-formulary and institutional tenders.
End-to-end CDMO services: Sterile lyophilized-powder vial contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tamper-evident tender-ready packaging and import/export coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Parecoxib for Injection Demands a Premium Manufacturer
Parecoxib for Injection occupies a distinctive place in modern post-operative pain management across every market. It is the analgesic an anaesthetist or surgeon reaches for when a patient needs strong, non-opioid pain relief in the hours after an operation but cannot yet take anything by mouth - and it is the one option of its kind that can be given by injection, because parecoxib is the only selective COX-2 inhibitor, or coxib, available as a parenteral. What makes it distinctive is twofold. First, it is a prodrug: parecoxib sodium is itself essentially inactive and is rapidly hydrolysed in the body by hepatic enzymes to valdecoxib, the active molecule that selectively inhibits cyclo-oxygenase-2. Second, that COX-2 selectivity means it controls pain and inflammation while largely sparing platelet aggregation and the gastric mucosa, which is why it is valued as part of a multimodal, opioid-sparing regimen where preserving normal clotting and gut tolerance matters. Because it is given parenterally to patients recovering from surgery, the dose from each vial must be exact, sterile, particulate-free and reliably the same from unit to unit, since the prescriber depends on a precise, ready, reproducible parenteral dose.
That clinical reality places real demands on the manufacturer. Parecoxib for Injection is not a ready-to-use solution but a freeze-dried product - typically 40 mg of parecoxib (as parecoxib sodium) presented as a sterile lyophilized powder in a vial, reconstituted at the point of care with about 2 mL of 0.9% sodium chloride to give a clear solution for intravenous or intramuscular use - so the assay and content uniformity must be exact and the cake must dissolve quickly and completely. Diluent compatibility is a genuine safety point that the manufacturer must build into the design and the label: parecoxib must be reconstituted with an acceptable diluent such as 0.9% sodium chloride, because reconstitution with Lactated Ringer's solution (or 5% glucose in Lactated Ringer's) causes the drug to precipitate, so reconstitution-and-diluent compatibility has to be characterised and clearly communicated. As a lyophilizate it is moisture-sensitive: residual water in the cake, measured by Karl Fischer, is a critical determinant of both chemical stability and reconstitution behaviour, so the freeze-drying cycle must be validated and tightly controlled. Because the active is a prodrug that converts to valdecoxib, the stability-indicating method must resolve and quantify parecoxib and its related substances - valdecoxib among them - without interference, and the right sterilisation strategy is aseptic processing of the sterile-filtered bulk followed by lyophilization rather than terminal autoclaving of the dried cake. The coxib class cautions - the cardiovascular thrombotic risk, the contraindication after coronary artery bypass graft (CABG) surgery, the risk of serious skin reactions, and sulfonamide hypersensitivity - must be clearly carried on the label. Choosing a Parecoxib for Injection manufacturer that treats the stability-indicating assay, related-substance control, residual-moisture and reconstitution-with-diluent-compatibility control, content uniformity, and particulate and endotoxin control as core engineering disciplines is what protects the patient at the point of care.
What Sets a World-Class Parecoxib for Injection Manufacturer Apart
A world-class manufacturer of Parecoxib for Injection invests in three areas that weaker suppliers underfund: a precise, stability-indicating assay of parecoxib with related-substance control - including valdecoxib - by validated HPLC, which a prodrug coxib demands; a robust, validated lyophilization and aseptic-fill process, which a freeze-dried, moisture-sensitive active requires from compounding through to the sealed vial; and tender-ready dossier support, including reconstituted in-use and diluent-compatibility stability data, for an analgesic procured through hospital-pharmacy and ministry-of-health channels. It starts with the active - pharmacopoeial- or in-house-specification-grade parecoxib sodium sourced from qualified, audited API makers, with full assay, related-substance and impurity profiling and certificates of analysis verified by the receiving laboratory before the material enters production.
Compounding, filling and freeze-drying then have to defend the assay, the clarity, the residual moisture and the reconstitution behaviour of a prodrug powder. The bulk solution is compounded in water-for-injection at the controlled pH that keeps parecoxib sodium soluble and stable, sterile-filtered through a 0.22 micron membrane and filled into vials under ISO Class 5 conditions, then freeze-dried on a validated lyophilization cycle and stoppered under controlled, low-humidity conditions, with the sterilisation and drying parameters locked in the master batch record. Filled units are 100 % inspected for fill, cake appearance, seal and particulate defects; in-process and release testing confirm the assay of parecoxib by validated HPLC, the related-substance (including valdecoxib) profile, residual moisture by Karl Fischer, reconstitution time and clarity with the recommended diluent, content and fill uniformity, visible and sub-visible particulate matter, and that endotoxin is held well within limits so the reconstituted solution is safe for intravenous and intramuscular administration. Because the active is a moisture-sensitive prodrug with a real diluent-compatibility requirement, assay accuracy, related-substance control, residual-moisture control and reconstitution-with-compatible-diluent behaviour are confirmed together so the assay, cake and clarity stay within specification across shelf life.
Quality Systems Behind Every Parecoxib for Injection
Every Farbe Firma Parecoxib for Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay of parecoxib against reference standards, control of related substances - including valdecoxib - by HPLC, residual moisture by Karl Fischer, reconstitution time and clarity with the recommended 0.9% sodium chloride diluent, content and fill uniformity, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and container-closure integrity for the vial format. Certificates of analysis are issued with full traceability back to each API lot, the primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, validated lyophilizers, sterilisation and depyrogenation equipment, validated aseptic filling lines with 100 % inspection, controlled low-humidity powder-handling areas, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because parecoxib is a moisture-sensitive prodrug coxib presented as a lyophilized powder, and the assay, related-substance profile, residual moisture and reconstitution-with-compatible-diluent behaviour drive both efficacy and safety, we treat the stability-indicating assay, the related-substance (including valdecoxib) profile, residual moisture and reconstitution-and-diluent compatibility as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under ICH Q1A long-term and accelerated (40 degrees C / 75 % RH) conditions, with reconstituted in-use and diluent-compatibility stability documented, so the assay, cake and clarity stay within specification across the labelled shelf life.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Parecoxib for Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables, including a broad analgesia, anaesthesia and peri-operative small-volume parenteral portfolio. For Parecoxib for Injection specifically, we supply the 40 mg lyophilized-powder vial under WHO-GMP conditions, reconstituted at the point of care with 0.9% sodium chloride for intravenous or intramuscular use, with country-specific strengths (including 20 mg), fill configurations, tamper-evident packs and pack counts available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier - including the stability-indicating-assay, related-substance, residual-moisture, reconstitution-and-diluent-compatibility, sterilisation and container-closure data package - ready to hand for registration and tender qualification.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability packages, reconstituted in-use and diluent-compatibility stability data, stability-indicating method-validation data, lyophilization-cycle, sterilisation and container-closure reports, translated package inserts and artwork - including intravenous and intramuscular administration instructions, reconstitute-with-0.9%-sodium-chloride and do-not-use-Lactated-Ringer's guidance, store-below-25-degrees-C storage directions, and the cardiovascular, post-CABG, serious-skin-reaction and sulfonamide-hypersensitivity cautions - for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination market. When a buyer needs Parecoxib for Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, line slot and shipment schedule delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the compounding, filling and lyophilization suites; our quality unit answers technical queries with primary data, not slogans; and our reviewer team - practising pharmacists and R&D scientists - can talk through API sourcing, the development of a stability-indicating assay for a prodrug coxib, related-substance and valdecoxib control, lyophilized-formulation design, residual-moisture and reconstitution-with-diluent-compatibility strategy, the validated freeze-drying cycle and aseptic-fill design, content and fill uniformity, particulate and endotoxin control, container-closure integrity and shelf-life choices in real detail. For a selective COX-2 inhibitor where dose precision, prodrug-to-active control and reconstitution reliability directly govern patient safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Parecoxib for Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Parecoxib for Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, validated water-for-injection systems, validated freeze-drying (lyophilization) and aseptic vial filling lines, controlled low-humidity powder handling, validated sterilisation, 100 % inspection and continuous environmental monitoring.
Which strengths and pack sizes of Parecoxib for Injection do you supply?
Our standard presentation is the 40 mg lyophilized-powder vial of parecoxib (as parecoxib sodium), reconstituted at the point of care with about 2 mL of 0.9% sodium chloride to a clear solution for intravenous or intramuscular use; a 20 mg presentation is also available. Custom strengths, fill configurations, vial formats, co-packed diluent, tamper-evident counts per pack and country-specific artwork are available under contract manufacturing agreements.
What is Parecoxib for Injection mainly used for?
Parecoxib for Injection is used for the short-term management of acute post-operative pain. It is the only injectable selective COX-2 inhibitor (coxib) and is a prodrug that converts in the body to valdecoxib, sparing platelets and the gastric mucosa relative to traditional NSAIDs; Farbe Firma verifies the assay, related-substance (including valdecoxib) profile, residual moisture, reconstitution-and-diluent compatibility, content uniformity, particulate matter and endotoxin at release so each vial delivers a precise, reproducible dose. It must be reconstituted with a compatible diluent such as 0.9% sodium chloride, and the cardiovascular, post-CABG, serious-skin-reaction and sulfonamide-hypersensitivity cautions of the class are carried on the label.
Can Farbe Firma support country-specific registrations for Parecoxib for Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability packages, reconstituted in-use and diluent-compatibility stability data, stability-indicating method-validation data, lyophilization-cycle, sterilisation and container-closure reports, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
What is the minimum order quantity for Parecoxib for Injection contract manufacturing?
MOQs vary by strength, vial size, lyophilization-cycle time, label complexity and dossier requirements. For our analgesia and peri-operative small-volume parenteral presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments